Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.78 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 2/20 | 0.67 |
| ▸ | MMP9 | P14780 | 2/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.64 |
| ▸ | ITGAV | P06756 | 1/20 | 0.64 |
| ▸ | CPB1 | P15086 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.64 |
| ▸ | TGM2 | P21980 | 3/20 | 0.64 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561005 | 1.00 | FOLH1 (0.78) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL464715 | 1.00 | FOLH1 (0.78) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL11875673 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL4173693 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL4173691 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL18907025 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157463 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL18907028 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157482 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157462 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| CN-119192214-B | Targeted binding fibroblast activation protein multimeric compound and application thereof | 杭州景嘉航生物医药科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119192214-A | Targeted binding fibroblast activation protein multimeric compound and application thereof | 杭州景嘉航生物医药科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20090048166-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | EPIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-7414105-B2 | Peptide dimer bonded to polyethylene glycol through amide groups; insufficient or defective red blood cell production | AFFYMAX, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414105-B2 | Peptide dimer bonded to polyethylene glycol through amide groups; insufficient or defective red blood cell production | AFFYMAX, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2008-04-03 | — | — | US | disclosed |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2008-04-03 | — | — | US | disclosed |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | FOLH1 4283/4885SIRT2 2667/4885SIRT1 3042/4885 |
| US-20090048166-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | FOLH1 722/4885SIRT2 4336/4885SIRT1 4168/4885 |
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PGF, F13A1, F11 | FOLH1 2308/4885SIRT2 4034/4885SIRT1 3432/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | FOLH1 3754/4885SIRT2 2590/4885SIRT1 2095/4885 |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | FOLH1 772/4885SIRT2 3424/4885SIRT1 3110/4885 |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | EPOR, PROKR1, PROKR2 | FOLH1 772/4885SIRT2 3424/4885SIRT1 3110/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | FOLH1 163/4885SIRT2 3220/4885SIRT1 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.